Pharmaron Beijing Past Earnings Performance
Past criteria checks 5/6
Pharmaron Beijing has been growing earnings at an average annual rate of 20.3%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 26% per year. Pharmaron Beijing's return on equity is 13.8%, and it has net margins of 16.8%.
Key information
20.3%
Earnings growth rate
18.4%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 26.0% |
| Return on equity | 13.8% |
| Net Margin | 16.8% |
| Next Earnings Update | 29 Oct 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pharmaron Beijing makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 11,502 | 1,928 | 1,895 | 474 |
| 31 Mar 24 | 11,485 | 1,483 | 1,883 | 465 |
| 31 Dec 23 | 11,538 | 1,601 | 1,895 | 448 |
| 30 Sep 23 | 11,424 | 1,553 | 1,966 | 402 |
| 30 Jun 23 | 11,272 | 1,575 | 1,950 | 381 |
| 31 Mar 23 | 10,887 | 1,474 | 1,887 | 320 |
| 01 Jan 23 | 10,266 | 1,375 | 1,749 | 282 |
| 30 Sep 22 | 9,545 | 1,582 | 1,533 | 219 |
| 30 Jun 22 | 8,793 | 1,682 | 1,355 | 171 |
| 31 Mar 22 | 8,057 | 1,664 | 1,147 | 162 |
| 31 Dec 21 | 7,444 | 1,661 | 1,033 | 152 |
| 30 Sep 21 | 6,849 | 1,423 | 954 | 146 |
| 30 Jun 21 | 6,226 | 1,258 | 856 | 127 |
| 31 Mar 21 | 5,664 | 1,317 | 820 | 113 |
| 31 Dec 20 | 5,134 | 1,172 | 761 | 105 |
| 30 Sep 20 | 4,717 | 1,008 | 691 | 89 |
| 30 Jun 20 | 4,314 | 865 | 636 | 79 |
| 31 Mar 20 | 3,953 | 594 | 605 | 75 |
| 31 Dec 19 | 3,757 | 547 | 574 | 63 |
| 30 Sep 19 | 3,499 | 437 | 547 | 51 |
| 30 Jun 19 | 3,274 | 378 | 525 | 44 |
| 31 Mar 19 | 3,089 | 346 | 498 | 34 |
| 31 Dec 18 | 2,908 | 333 | 461 | 32 |
| 30 Sep 18 | 2,713 | 300 | 686 | 46 |
| 31 Dec 17 | 2,294 | 231 | 374 | 23 |
| 31 Dec 16 | 1,634 | 177 | 280 | 0 |
| 31 Dec 15 | 1,128 | 74 | 221 | 0 |
| 31 Dec 14 | 790 | 21 | 155 | 0 |
Quality Earnings: 17Q1 has high quality earnings.
Growing Profit Margin: 17Q1's current net profit margins (16.8%) are higher than last year (14%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 17Q1's earnings have grown significantly by 20.3% per year over the past 5 years.
Accelerating Growth: 17Q1's earnings growth over the past year (22.4%) exceeds its 5-year average (20.3% per year).
Earnings vs Industry: 17Q1 earnings growth over the past year (22.4%) exceeded the Life Sciences industry -9.9%.
Return on Equity
High ROE: 17Q1's Return on Equity (13.8%) is considered low.